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First source of intelligence for the pharmaceutical industry
Introduction After a decade of e-marketing and e-detailing, which included much hype and expectation, the dust is beginning to settle on a phase of more realistic expectations and approaches.
This conference, Online Marketing and eDetailing, organised by eyeforpharma, showed signifi cant evidence that physicians are at last embracing online technology on a regular basis. The question of whether doctors are using the internet can fi nally be laid to rest: studies show that between 70% and 97% of European Union (EU) physicians use the internet on a daily basis for accessing clinical information.
So how are pharmaceutical companies responding, and what is e-marketing now being used for? This conference showed that the main key areas in which e-marketing is currently being deployed by pharmaceutical companies are e-detailing, customer relationship management (CRM), healthcare provider (HCP) portals and consumer compliance applications.
It was widely stressed that the days of simply doing 'e' are over; business principles must be applied to any 'e' project. Any e-marketing or e-detailing project must start with clear business objectives and determine which key performance indicators (KPIs) should be measured to determine whether the business objective was met and what fi nancial marketing return, or return on investment (ROI), was achieved.
In terms of execution, 'mundane things matter', and quality of content and execution are, as ever, crucial. So, too, is involving all key stakeholders from the beginning and getting their buy-in and involvement.
The needs of the customer were a frequent topic in several presentations, and the concept of being customer-centric rather than product-centric was highlighted. Another topic of increasing importance was the integration of any e-marketing/e-detailing programme into some kind of CRM system and feedback loop. In fact, this concept fed into another key topic -the integration of e-marketing with the overall marketing mix. The theory of dropping the 'e' and ensuring all marketing is digitally enabled was highlighted in several presentations.
Dr Andrée K Bates
July 2006 About the author Dr Andrée Bates is the Managing Director of Campbell Belman, a company that applies sophisticated analytical processes to quantify the sales impact of specifi c marketing programmes for pharmaceutical brands. These analyses determine the fi nancial return for individual sales and marketing activities, as well as the optimal synergistic combination of activities (and budgets) Andrée's career has encompassed academic, clinical and pharmaceutical positions internationally. She has gained wide recognition within the healthcare industry internationally for ROI and marketing effectiveness measures in pharmaceutical marketing. She is the author of many publications on this topic in peer-reviewed journals. In addition, Andrée has been invited to lecture on e-detailing ROI in the Pharmaceutical MBA programme at INSEAD Business School and on marketing ROI at the Center for Pharmaceutical Marketing Studies, Erivan K. Haub School of Business, St. Joseph's University, Philadelphia.
Andrée can be contacted via email at ABates@CampbellBelman.com
The business case for e-marketing
A decade of e-marketing: what's it been all about?
Expectations and outcome 'Less hype, more realism' was the underlying message in the opening keynote address by Chairman, Len Starnes (Schering AG). To mark the 10th anniversary of e-business in Europe, Starnes took the audience through the e-business hype cycle from 1996 to 2006 ( Fig. 1 ). In 1996, early adopters took on initiatives such as websites and early e-detailing models. Two things stood out at that time. First, the notion of the 24/7 representative and, second, the importance of the health information seeker. "Ten years ago we had great expectations," said Starnes. "Some people made a lot of wild predictions such as 'we can forget the rep because now, with the internet, we have reps 24/7.' Some of the hype went too far, but others did not go far enough."
The way users consumed and interacted changed dramatically with the digital era, enabling conversations that were not previously possible in the mass communication era. These networked conversations enabled new forms of social organisation and knowledge exchange to emerge.
The organisational roller coaster
The hype surrounding e-business led pharmaceutical companies to address the area and thus began the organisational roller coaster, which varied from company to company. Large centralised e-business departments were set up for most companies and e-initiatives began. Then, when the hyped expectations were not met, disillusionment set in, and the industry went through an e-business trough of despair. The centralised departments were largely disbanded and, instead, smaller e-business intelligence groups who worked with or within local business units and brand teams were created.
Success issues
Success in e-business comes down to how well it is executed. Starnes pointed out that 'mundane things matter'. High-quality content, simple intuitive design, credibility, trust, privacy and search engine marketing are all important. To be successful, e-business must execute the mundane things properly, as well as be closely aligned with integrated relationship marketing teams.
KPIs have to be tracked and matched with objectives and expected outcomes. The main KPIs tracked in e-business were HCP relationship building, consumer/ patient relationship building, disease and treatment awareness, conversion to brand and retention on brand (compliance). Whereas in today's market one might expect that increases in prescribing and compliance would be the main KPIs tracked, interestingly, even in Europe, it was shown that the majority of all e-business (40%) is aimed at disease and treatment awareness. The next most popular area is patient/HCP relationship building (23%).
Where are we now?
Today is the dawn of a new era -the era of enlightenment ( Fig. 1) company may give another bundle at minimal cost. The internet is one channel that is able to provide the right service, to the right customer, at the right cost. This will not change moving forward.
The internet is one channel that is able to provide the right service, to the right customer, at the right cost HCP portals are another area expected to deliver signifi cant business value in the future. If one examines HCP portals within the CRM context, they are integral to the CRM/SFE strategy and crucial for delivering customised service bundles as the online needs and preferences of the doctor are better understood.
Given the high cost and decreasing impact of the traditional sales force model, e-detailing is expected to become a viable alternative to the sales force arms race. This view was strongly shared in an eyeforpharma survey of pharmaceutical industry executives conducted in 2005.
However, e-detailing still faces some barriers: a lack of understanding among senior managers who discuss it out of CRM/SFE context has led to concerns over the high costs, uncertainty about how to scale up (brand, business unit, regional or global) and confusion about different vendor models. Starnes pointed out that this has bred uncertainty about its ROI. Enter the digitally enabled representative. The idea is that each representative would have a tablet PC, all details would be housed electronically, the representatives would carry out doctor details (either live or via telephone or online) and all data around them would be tracked and fed back into the CRM system in a closed-loop application. Feedback would also be available for the representative the next time they see that doctor. Serono and Janssen are already doing this with impressive results.
According to Starnes, online patient support programmes will also emerge in the future environment, to plug the 'leaky bucket syndrome'. The marketing efforts around this will switch from acquisition to retention, as the e-channel is one of the best media for most compliance approaches. Regulations will be revised to enable this. "We are seeing quite a change in what regulators will allow us to do year-to-year as new concepts are explored," he said. "For example, compliance programmes for patients are not addressed at all in EU Directives, and if we actually have the chance to talk to regulators, in some markets, they often will change their views and allow us to do things we couldn't do before."
Starnes cautioned the audience to keep in mind that direct-to-patient (DTP) is not the same as direct-toconsumer (DTC). DTP encompasses the restricted provision of information and support services to a patient already on a drug. This will not result in new prescriptions, but repeat prescriptions. DTC, on the other hand, is an offence, and pharmaceutical companies in the EU are not allowed to issue an advertisement that is likely to lead to a new prescription. He showed that next-generation compliance had moved on -it was now combined with segmental patient data and behavioural modelling techniques. Starnes stated that more two-way dialogue and more community building will signifi cantly increase the value of consumer-and patient-directed initiatives -and help engender trust in the pharmaceutical industry. 
Key lessons of the decade

85% of UK doctors and 83% of Belgian doctors use the internet several times a day
The panel agreed that this usage of the internet mirrored their current usage, and also mentioned that whereas the bulk of their usage was in the early morning and evening, they also logged on several times during the day.
Dr Bejjani revealed how, in his hospital, online forums have been developed for physicians to use to discuss topics pertinent to their specialist areas and specifi c patient concerns. He said that online is the easiest way for the physicians to stay in contact, adding that the forums had been very successful and achieved many postings each day.
) also focused on the HCP viewpoint. Elkington reported on research conducted jointly in collaboration between UBM and IMS, focusing on how UK GPs use the internet.
The study found that 97% of UK GPs use the internet to fi nd work-related information daily or almost daily, and 82% of UK GPs use it at work, daily or almost daily. Interestingly, it found that over half of GPs (63%) access the internet during patient consultations.
The survey reported that GPs had the highest level of trust for peer content -especially from independent medical community publishers, but had limited use for pharmaceutical company websites. Ninety per cent use Google regularly to fi nd what they need, which in the main constitutes clinical information. However, although GPs use Google extensively, the research showed that many doctors feel there are too many links with disappointing relevance, and too many advertisements. Elkington suggested that, since physicians clearly turn to the web for information, this points to the potential need for a medical search engine, created by an independent medical community, that only showed relevant results. This type of search engine would, he said, need to: understand the taxonomy of diseases and therapies anticipate the real search goals of the user search the deep web personalise the experience allow the user to select where they searched (i.e. web, government, etc.).
Pulse (the online GP magazine) is, in fact, currently developing this kind of medical search engine for physicians.
There is potential need for a medical search engine, created by an independent medical community
Pharmaceutical marketing applications of the fi ndings
So, in the light of this research, what do pharmaceutical marketers need to consider? Elkington compared traditional representatives, trade press, continuing medical education events and the web in terms of reach and frequency, richness and ROI (Table 1) . From this comparison, it was concluded that the web was a highly viable platform for communicating with physicians. Doctors don't want adverts but they do want practical help with the following: e-Detailing focus: why and who?
Why e-detailing?
Theresa Broemse (Bayer Healthcare) began by saying that e-detailing, when properly planned and executed, can help brand teams to be more relevant to the physician. Broemse focused on traditional sales effi ciency, or rather, ineffi ciency. She provided a summary of various studies on representative interactions with physicians showing that access to physicians is decreasing (with a doubling of 'no see' physicians in the past decade) and that the amount of time spent interacting with doctors is also falling. A study by McKinsey Consulting showed that of 100 representative doctor visits, in only 8 will the representative actually speak with a physician. However, a sizable proportion of physicians in all countries (between 45% and 80%, depending on the country) said that they would like to replace traditional details with e-details, or have e-details as an option to supplement traditional details.
The benefi ts of e-detailing for physicians are indeed numerous: they are more fl exible with regard to time, location and length than traditional details; access levels increase; and interactions are more effi cient and convenient. Likewise, for pharmaceutical companies, e-detailing allows rapid message distribution, brings an increase in reach and consistency of messages and, crucially, is cost-effective.
There are, of course, potential threats to the use of e-detailing. These include: lack of awareness and slow adoption work and information overload conservatism; perceived value across the senior manager level the heterogeneous healthcare environment.
Bayer's experience
Bayer uses e-detailing for nine of their brands, in 16 countries, and has 31 modules. Broemse provided e-detailing case studies of Cipro XR in the USA, Levitra in Germany and Levitra in the UK. For all the e-detailing case studies shown, success metrics were measured and signifi cant improvements were found in the e-detailed group compared with control groups. They found e-detailing to be successful in driving awareness and that it had a signifi cant impact on message recall. It also helped differentiate brands, driving increased usage: brand prescribing for doctors who had participated in the e-detail more than doubled. e-Detailing also had a signifi cant impact on physicians' stated intent to use a brand, with fi gures almost doubling in this area. Critically, the e-details were well received and over 80% of physicians said they would like to be asked to participate in further modules. In summary, Broemse identifi ed the 10 critical success factors in e-detailing: 
Physician e-detailing preferences
In 2005, Manhattan Research 4 conducted a study of physicians which showed that only 12-13% had participated in e-detailing in the previous 12 months, whereas a signifi cant 41-42% said they were not familiar with e-detailing. In contrast, according to Datamonitor in the same year, physicians reported preferring a mix of technology-based detailing and live detailing, with 53% preferring individual self-directed e-detailing (i.e. from a website), 27% preferring sessions with a sales representative remotely (i.e. tele-/videoconferencing) and only 9% preferring e-detailing services during the course of a live detail (i.e. on a handheld device or laptop).
Physicians prefer a mix of technology-based detailing and live detailing
Forrester Research examined how to incentivise physicians and published the results of a study carried out in 2003, in which 40% of physicians stated that the main reason that they take an e-detail is the honorarium. Over half the sample reported that such a bonus would 1.
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infl uence their decision. Rockmyr said that her own experience suggested that providing something as an incentive did increase response rate. She had conducted two different e-detailing programmes, one offering a valuable item and one without anything to offer. The e-detail with the 'give-away' had a response rate of about 15%; in the e-detail which offered no gift, the response rate was below 5%. Some of the incentives offered to physicians in Europe include cash, promotional items, tools for the physician's practice, medically relevant textbooks, product samples and patient education resources.
Consumer e-detailing considerations
A recent change to the Association of British Pharmaceutical Industry code of practice (Clause 20.2 supplementary information) 5 about providing factual information for patients states that: "Reference information is intended to provide a comprehensive upto-date resource that companies should make available on their websites or by way of links from their website or by some other means." Evidently, providing disease awareness to patients, in conjunction with e-detailing the physicians, is a potentially powerful option.
Nurse e-detailing experiences
Rockmyr moved on to nurses as an e-detailing target group and discussed her experiences with a campaign containing educational content aimed at gastrointestinal specialist nurses. The e-detailing had impressive results despite the fact that no incentives were offered and, in fact, the return rate was actually higher than for an average physician campaign.
Pharmacist e-detailing importance
With the push towards generics and replacing branded drugs, pharmacists play an important role in informing patients. As such, the relationship between the pharmacist and the pharmaceutical company is becoming increasingly important. By providing educational information with frequent updates, a relationship with a pharmacist can be established. Pharmacists are another group that must not be ignored when choosing e-detailing targets.
Payer e-detailing importance
A critical player in drug funding and reimbursement is the payer. In most markets there are a few key customers spread across a large geographical area, meaning that appointments are diffi cult to make. And yet the timelines are critical as they must be impacted before key decisions are taken. This group is a prime target for e-detailing.
What makes a good vendor?
The conference was attended by a signifi cant number of e-detailing vendors. 
What makes a good pharmaceutical client?
Rockmyr also discussed what would make a good pharmaceutical client for a vendor and suggested a few key areas where, perhaps, companies could improve. These included: a willingness to learn by running a programme evaluating, sharing and adjusting the process having content aligned to strategy rather than just getting an agency to put their detail online integrating with the sales force management buy-in.
e-Detailing focus: implementation issues and case studies
Choosing the right e-detailing approach
Two presentations provided case studies that illustrated how alternative e-detailing approaches can make the difference between success and failure.
3M Pharmaceuticals' experience
The fi rst of these was a presentation by Dave Clarke (3M Pharmaceuticals) who outlined two case studies of different forms of e-details that his company had undertaken.
Case study 1 -The fi rst case study involved a telephonic co-browsing model, targeting 2500 primary-care physicians in the UK and Netherlands. Recruitment was via direct mail and representative invitation. Only 12% of the group offered the e-detail
took up the invitation. Deployment was via a call centre manned by three members of the sales force, and the study was conducted for 6 months in one wave. The study resulted in an extra three new patients on brand per doctor detailed, with an ROI of 1.5 (Table 2) .
Although e-detailing did increase prescribing somewhat, the results were less than optimal. Reasons suggested for this were that the e-detailing was not integrated into the marketing mix, despite the fact that representatives were included in the process. The e-detail was perceived as being commercially biased because the recruitment came directly from 3M, which hampered enrolment. In addition, one wave was thought not to be enough to have a suffi cient impact on prescribing.
Case study 2 -The second case study involved a self-guided internet-only model. The target audience was both primary-and secondary-care physicians in the UK. Recruitment and deployment were via a direct monthly email from an independent doctors' portal. The study was conducted over 12 months with repeat waves. This case study leveraged the success of the fi rst case study by improving targeting and conversion and also by refi ning segmentation and messages. The results were 11 new patients on brand per doctor detailed, and the ROI was 4.5 (Table 2) .
Clearly, the use of an independent portal for recruitment purposes led to an increase in response rate compared with that in case study 1 (Table 2) , as the e-detail was perceived to be less commercial. Multiple waves with clear messages also enhanced the results. These results are consistent with several e-detailing studies.
Lessons learned -The key fi ndings of both projects were the need for:
target audience segmentation to be refi ned to meet objectives key messages to be customised repeat e-details to reinforce the effectiveness.
Clarke said that the product being detailed should optimally be either a new product, a late life-cycle product, or have either a new treatment indication or new scientifi c interest.
Pears Health Cyber's experience
Vladimir Finsterle and Tomas Vetrovsky (Pears Health Cyber) also examined the question of how to choose the right e-detailing approach. How to change prescribing behaviour became a major focus. Behavioural change follows the path of interaction, followed by self-generated thoughts, leading to a change in behaviour. Interaction requires four main components -information, incentive, emotion and a social driver -to move it towards behavioural change. Depending on the situation, and objective, varying degrees of these four should be used.
Interaction requires four main components -information, incentive, emotion and a social driver -to move it towards behavioural change
Finsterle and Vetrovsky used case studies involving drugs at different stages of the product life cycle -from new product launch to antigeneric strategy -to articulate their fi ndings. Two of these drugs, one at the 'change of treatment paradigm' stage of the life cycle, and another in an antigeneric strategy, illustrated how these different stages of the product life cycle affected the implementation of e-detailing.
Case study 1: new treatment paradigm for Risperdal -This study targeted UK psychiatrists, and aimed to increase Risperdal's share of voice, differentiate against a competitor and spread information about the new indication for Risperdal. To recruit, two types of direct email were deployed, one using Risperdal branding, the other Janssen branding. The Risperdalbranded email received twice as many responses. The project used a distant e-detailing mechanism -a standalone iCampaign involving no representatives. An action centre was provided at the end of the e-detail, and 48.9% of doctors clicked on this for further information and to request a representative visit. As a consequence of the programme, representative access increased signifi cantly. The study showed the value of pre-testing recruitment methodology and of including a request for further interaction at the end of the e-detail.
Case study 2: antigeneric strategy for Omnic Ocas -The second case study targeted urologists in the Czech Republic, the aim being to launch a line extension that would defend against a competitor launching a cheap generic version of the same molecule.
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Despite showing no new information, compelling web content integrated with one-to-one interaction with the sales force resulted in a 95.15% conversion rate over four waves. e-Details had viewing peaks at midday and late in the evening. There was also a signifi cant increase in representative access, and an increase in IMS market share for Omnic Ocas (Fig. 2) .
Clearly, the approach taken with an e-detail must be chosen according to the needs of the product, and by keeping in mind the four components of interaction: information, incentive, emotion and a social driver.
The approach taken with an e-detail must be chosen according to the needs of the product
Is the devil in the e-detail?
Austin Wilson (Framfab) focused on the fi ner points of a successful e-detail implementation. Traditional detailing is, of course, still going strong in the pharmaceutical industry, but Wilson cited a cause for optimism for e-detailing. However, e-detailing is not, he said, a silver bullet, and the details of implementation must be carefully considered to ensure success. Recruitment is a crucial area, with multiple recruitment channels being the most effective, and also mitigating the risk. Nonetheless, 'no see' or 'diffi cult to see' doctors do not automatically agree to e-detailing and often remain diffi cult to access via this channel. In fact, although such doctors can still be targeted, the cost per detail will be more expensive if they are the only target segment.
ROI issues
In terms of ROI, one problem we have when comparing e-detailing with traditional detailing is the fact that with e-detailing the numbers need to be scaled up in order to get the costs lower than those for the traditional fi eld option. However, if this is done in combination with good execution, it should provide a cost-effective channel. Many e-detailing pilots have shown hard ROI and an impact on sales, but this depends on strategy and implementation. On some occasions ROI has been less than 1, whereas in others it has been up to 4.5. One issue with return that has hampered some e-detailing pilots has been a critical mass issue in terms of the size of the programme, making it diffi cult to separate increases in prescriptions from noise in sales data. However, many companies measure soft metrics from eDFU (e-detail follow-up) and these have often found an improved recall of brand messages with e-detail compared with traditional detailing, a high credibility of messages delivered and that the intent to prescribe is similar to that seen with the traditional approach.
The ROI metrics of e-detailing over the past decade have shifted focus along the way. In the early days, the main considerations were physician connectivity, access and usability. Then, around 2000, the industry started focusing on cost per e-detail, minutes per e-detail and response rates. By 2004, the focus had shifted to campaign ROI, eDFU attitude surveys, and prescription and share increase. From the beginning of 2006, the focus has shifted again, and now the key focus in metrics are physician segment ROI, SFE, call optimisation and promotional mix optimisation.
Adding value to e-detailing
Looking at the e-detail value chain, it has been shown that challenges exist all along the chain, but gaining the benefi ts of e-detailing involves shifting to a more customer-centric approach of marketing, rather than product promotion. To do this, a company needs to build synergies between the promotional channels and optimise traditional SFE with e-detailing.
Another component that assists in this is capturing customer-specifi c information and, more pertinently, using it. With e-detailing everything can be tracked, so it is important to ensure that the e-detail is not 'one size fi ts all' and to segment physicians in order to deliver differentiated services relative to their needs. Different segments will respond differently to e-detailing promotions, so messages must fi t physicians' needs. Providing feedback to the front-line sales teams is also an important element not to be overlooked. Doing this can be as easy as sending automated emails or as complex as full CRM implementation. An example of how this would look is shown in Figs 3 and 4.
Research results
Wilson then gave results of a small 'test the temperature' survey conducted jointly between eyeforpharma and Framfab.
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In general, this survey found that primarycare-focused e-details were mainly used to drive launch impact, maintain frequency and be a cost-effective promotion for non-sales-force-promoted products. In secondary care, the focus of e-detailing was found to be mainly to supplement representative contact and provide value-added services.
How to create cost-effective e-details
So, how can you create more cost-effective and value-driven e-detailing? One option, said Wilson, would be to use enterprise CMS technology to drive down the localisation of e-detailing. By using this, it is possible to create a fl exible series of templates for a global e-detail and to localise the templates using a local branch of the template in the markets. Irina Osovskaya (Janssen-Cilag) showed how this approach had been implemented by Janssen. When creating a global e-detail template, it should be fl exibly built to accommodate adaptable functionality and technology, and then localised cost effi ciently by the markets. More value could be obtained by splitting funding between local and central markets. In doing so, central costs should cover programme components that can be leveraged in multiple markets, whereas local markets should drive and fund the local components. An illustration of how this could work is outlined in Fig. 5 .
Crucial aspects for success
The crucial aspects for success are understanding where your customers are in the sales process, and providing multiple paths through the e-detail to personalise for individual physician segmentation and differentiation. Secondly, it is important to recognise that e-detailing is a numbers game and that, as such, multiple recruitment strategies using multiple channels are key. Finally, content is still king. An e-detail should not simply be an online version of a detail but should be able to adapt to the user's needs and differentiate according to those needs. In addition, organisational readiness and the empowering of the sales force must also be considered. A combination of management buy-in, sales and marketing team buy-in, sales force buy-in and medical/ regulatory buy-in is essential.
A combination of management buy-in, sales and marketing team buy-in, sales force buy-in and medical/regulatory buy-in is essential
Wilson stated that, with more companies adopting e-detailing methodology, the landscape will become more cluttered and it will be increasingly diffi cult to recruit and retain physicians. Therefore, he recommended that pharmaceutical companies must: If companies get this right, they can control the solution, and make the best use of the customer data and insight gained.
e-Detailing focus: how to create a practical action plan
Best practices action plan to maximise e-detail potential
Osovskaya discussed how to develop a best-practice action plan. She explained that until Janssen changed its old approach, its e-detailing results had been mixed. However, since they created a central group, the responsibility of which is to sponsor the initial fi xed project costs so as to decrease the entrance barrier for 
SLOW ADOPTORS
Call by the sales-force is arranged At this early stage, clearly defi ned objectives for e-detailing must be set. One approach is for the central team to hold an initial workshop with the local stakeholders in which they clearly defi ne objectives and key messages, and reach a consensus.
NON-ADOPTORS
Once the central team is in place, an appropriate vendor is required. Janssen wanted one that worked solely in pharmaceutical marketing, with particular experience with large pharmaceutical companies, and had a track record for successful e-detailing projects through turnkey solutions.
Once a vendor has been selected, the development of an integrated platform to handle campaigns is needed. Osovskaya suggested that an open solution platform such as JAVA or XML works well, as it needs to be fl exible, scalable and able to be integrated into the CRM system with monitoring dashboards. The platform should enable the development of several templates that can then be localised for the local campaigns.
Osovskaya gave examples of how e-detailing had been successfully conducted, utilising a central template with localisation by affi liates, for brands such as Durogesic D-TRANS, Risperdal, Topamax and Risperdal CONSTA.
Six-step action plan
Her six-step action plan, after gaining internal buy-in, setting objectives and choosing key messages, is as follows:
Profi le -target non-called, hard to see, vacant territories; segmentation and targeting Recruit doctor -through telemarketing, fi eld promotion, e-mail, mail, etc. A multichannel approach using postcards, mails, emails, outbound calls and CD ROMs has been used within Janssen, along with incentives for signing up. Osovskaya's recruitment channel of choice is e-mail.
Deliver details -customise detail according to doctors' needs; usually three 'waves' or iterations of detail
Prompt further action -participate in survey, accept representative visits, order samples, attend CME, etc.
Integrate information -use CRM to supply data and learning back to fi eld and marketing
Measure impact -learn from experience and share best practices.
Osovskaya concluded that companies need to put their audience fi rst and that matching their content needs is king. An e-detail should form part of a campaign, with follow-up activities and CRM integration. To maximise response, as many different channels as possible should be used, collecting as many opt-in email addresses as 1.
2.
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5.
6. possible along the way. Osovskaya advised teams to send out reminders, as these can increase response rate from 20% to 50%, offer incentives and, crucially, make it easy. A fi nal reminder was to remember to involve the regulatory teams as early as possible.
Companies need to put their audience fi rst and matching their content needs is king e-Detailing and marketing mix integration
Vancoppenolle (MediQuality) discussed the integration of e-detailing with the sales force. He said that both the sales force and internet have a similar mission and, when used in combination, become a very powerful way to increase reach and frequency. He outlined the advantages and disadvantages of several media used in pharmaceutical marketing (Table 3) .
Vancoppenolle cited survey data from an online physician study in which he asked physicians to what extent they felt the internet should replace, complement or decrease sales force activities. The survey showed that 25% of physicians would like to see no representatives and have only e-detailing, though for existing brands, over three times that percentage thought e-detailing should complement traditional approaches. Vancoppenolle stated that many companies want to know how to free up representative time on mature products, and focus sales force activity on new products. These fi ndings may provide an answer.
According to Vancoppenolle, the top four things physicians consider very valuable on the internet are:
clinical information about a specifi c therapeutic area (57%) drug information (49.5%) literature reviews about specifi c areas (26.5%) systems enabling the posting of questions to an expert (24.5%).
Key points for integration
Vancoppenolle said that it was important to keep several points in mind when integrating: make it interactive, manageable, customised, adaptable and trackable, and offer user support. There are, of course, barriers to integration: it requires several departments to work together, which can be diffi cult to organise; a decent budget is required; internet expertise is essential; and managing change can be a challenge. Vancoppenolle suggested that to ease the process for pharmaceutical companies, working with a supplier can reduce the risk and opportunity costs, as well as reduce the stress on an organisation. was driving growth in the area. An increase in high-speed internet access means that more doctors can access heavier content. Other drivers are down to the e-detail itself. These include things such as well-designed and relevant activities with consistent messages, suffi cient sampling and a proven ROI for the pharmaceutical industry.
Moving e-detailing beyond current limitations
Data from the University of the Sciences in Philadelphia show the potential market growth for e-detailing in the next 3-5 years (Fig. 6) . The panel then linked this growth with the e-business hype cycle (see Fig. 1 ) and agreed with Starnes' earlier suggestion that we are now in the phase of enlightenment, characterised by focused experimentation and solid hard work by a diverse range of organisations leading to a true understanding of the technology's applicability, risks and benefi ts. In this phase, commercial off-the-shelf methodologies and tools become available to ease the development process.
So, can e-detailing become an integral part of the 'traditional' sales and marketing mix? The panel suggested that ideally we should remove the 'e' and have a digitally equipped representative force. This doesn't mean just putting the details on a laptop, but rather providing physicians with a digital system that suits both representatives and physicians, and utilises the power of e-details by integrating all the elements that make them successful. In some cases it would complement the sales force, and in others it may replace the sales force. Research has shown that whereas some doctors prefer e-detailing to traditional detailing, others prefer traditional approaches to e-detailing; many prefer a combination. The industry must, therefore, focus on providing information to its customers in the format they personally want.
One panellist suggested that the pharmaceutical industry is relatively back-to-front compared with other industries, as it is very sales-force driven, with marketing seen as support. In contrast, other industries are marketingled with the sales force used for support. Potentially, e-detailing could redress this balance.
The industry must focus on providing information to its customers in the format they personally want
Another discussion point centred around the 'pull marketing' approach, asking: can you transform customer relationships and increase market share with a valuable information/educational resource, not just a product sell via e-detailing? The consensus was that companies should utilise the benefi ts of the medium to create something that pulls customers in rather than pushing out to them. If you know what your individual physician customers want, you can utilise the pull technique to meet their needs more, which can only be of benefi t.
The panel concluded that e-detailing was here to stay but will eventually grow out of 'e' and become integrated within the marketing mix. The balance of tactics and strategies will change, with more resources being devoted to evaluation of the approach.
Organisational issues
Organisational processes
Mariusz Borkowski (Sanofi -Aventis) outlined his experiences with a pilot programme conducted in Poland that provided lessons to help organisational processes maximise success. The programme involved loaning internet-connected palmheld devices to physicians. The devices were loaded with clinical decision support information, drug indexes and abstracts of clinical studies. They also contained postgraduate education, educational fi lms, congress reports, KOL opinions, educational points and advertising materials.
The valuable content was only part of the project. The doctors had to agree that in exchange for the loan, they would participate in a simple clinical trial of a SanofiAventis drug and would input anonymised patient data into the device for an agreed number of patients taking the product. This would help with the development, improvement and evaluation of a clinical decision support system. The device allowed easy, two-way information exchange with the participating physicians.
Sanofi -Aventis' objectives were to improve their company image while building relations with these physicians. In the process, they would use the device as an advertising medium, as well as a way of providing feedback from physicians. An added bonus was that prescribing of their diabetes products also increased among these physicians.
Lessons for organisation
The experience raised some issues over organisational activities within pharmaceutical companies. First, prior to the project, Borkowski found that different brand teams often do not have a clear vision of how to use the internet to realise business goals, and have varying levels of internet knowledge. Within the company there was a lack of coordination between internet activities, and employees saw the internet as an additional activity, which led to internal resistance to its use.
Borkowski built systems to overcome these organisational issues. A crucial early step was to ensure that management of e-projects included all parties involved in client relationships (e.g. product managers, medical representatives and scientifi c affairs). Integrating these parties and getting internal buy-in was critical to the success of the project. Moreover, it ensured that the project was not delayed while waiting for approval from one or more parties. Borkowski added that a good way to approach this was to start with a global template for a project and then allow it to be customised locally, thus decreasing local team resistance.
Refi ning the strategy: targeting is key
Aleks Aísa (Novartis) focused on how to refi ne strategy to target e-marketing initiatives effectively. He started by explaining that he thought that tracking traditional metrics was not a good idea with respect to e-channels. He said that by focusing on ROI one may as well turn to a clairvoyant for answers as there are too many assumptions made within each step of an ROI equation. According to Aísa, measuring return on traditional metrics was not unlike being lost in a cloud, whereas when measuring return on e-business, the cloud shrinks slightly and, although there is some fog, you can see a lot more clearly. He said we should start to look at strategy from a new point of view: the knowledge of our customers that allows greater segmentation and targeting than any other medium. He said that much marketing was simply 'let's be' and a web presence was created simply to be there. Now we can utilise this medium for highly segmented and targeted campaigns, rather than just sitting and waiting and 'being'. By integrating everything within a CRM system we can capture all interactions from each customer and measure the impact from a wide range of interactions with that customer rather than one e-channel activity. In so doing, we can create predictive-adaptive marketing strategies tailored to each customer, thus shrinking the gap between results and predictions.
ROI and success measurement e-Detailing case studies and ROI
The concept of ROI appears to be a confusing one for the pharmaceutical industry. Table 4 shows research from ANA/Forrester Research on how respondents defi ned ROI. In fact, the real defi nition of ROI -incremental profi t generated -is not even mentioned.
Francesco Convertini (Sanofi -Aventis) described how Sanofi -Aventis uses sales representatives to detail over-the-counter (OTC) drugs to doctors. It decided to implement an e-detailing project to understand whether it would be possible to provide ROI in their detailing. Convertini and his team felt that while they could forecast a macro picture of ROI for a brand, they were not certain how they could calculate the ROI on each and every activity. They decided that the project should be measurable according to clear, specifi c objectives around the effectiveness of the e-detail and the business gains. These were divided into qualitative objectives (test e-detailing, understand approach towards the product) and quantitative measures (brand awareness, click through rate [CTR] redemption).
Product background
The product chosen was Enterogermina, an oral suspension of bacteria spores offered in single doses that restores the intestinal bacterial balance in the case of an intestinal disorder. Enterogermina was launched in Italy in 1958 and became an OTC product in 1999. It is a market leader in the Italian market with a market share of 40.1% volume and 37.4% value.
The project's aim was to deploy an e-detailing programme to support a product that has a long history in the marketplace and to determine whether e-detailing worked in this situation. However, determining the effectiveness of an e-detailing programme is a challenge due to multiple marketing. In Italy, physicians are important OTC product infl uencers.
Targeting and recruitment
The programme targeted 12,000 GPs, with Sanofi -Aventis recruiting its physicians via e-mail using a provider that could reach 80% of Italian GPs. They divided Italy into two areas. In one area, all 10,000 physicians were e-detailed. The other area was divided into two groups: one received e-detailing, the other did not. Physician interviews prior to the e-detailing were conducted via a call centre in order to determine brand awareness and share of voice. The e-detailing lasted for 6 months, after which follow-up interviews were conducted.
The approach comprised a self-directed website. Once on the general website, 60% of physicians clicked through to the formal e-detail. Tracking was done both pre-and post-detail on the representative panel to monitor brand awareness, brand equity, attitude towards prescription and e-detailing recall. In addition, GP online behaviour was tracked with respect to a number of factors, including CTR, average time of visit and loyalty. Tracking was carried out to monitor trends between pre-launch of the e-detail and waves 1 and 2, as well as against groups in which no e-detailing had taken place.
The key ROI drivers appeared to be list quality, the ROI triangle (opens/clicks/conversion, corresponding to awareness, interest and conversion which are tracked as leads, prescription sales and downloads), timing (they found one must always send multiple reminder emails and allow at least 6 months if not a year to measure results) and editorial planning.
Results
CTR was 39%. e-Detailing moved the brand from 97% to 100% awareness, and brand favourability increased by over 50%. "e-Detailing gives us much more information about what the physicians need," said Convertini. "And we get this feedback much more quickly than we can get from a sales rep." discussed the tyranny of the ROI metric and why senior managers do not demand the same rigour with other channels. One panel member suggested that more help on this topic was needed from the business intelligence teams, so that they could look at objectives and help decide which metrics are most appropriate to measure in determining whether objectives were met. According to Wesley, this channel has been subjected to more rigour than any other media channel, and we now have proof that it works. The whole ROI argument should, she said, be put to bed and we should get on with it as we do other channels. Discussion then centred around the different KPIs and how they fared (Table 5) That pesky ROI (roundtable discussion)
How to select the right KPIs
Interspersed with the presentations on day two was a roundtable discussion on the measurement and ROI of e-marketing programmes, led by Dr Andrée Bates (Campbell Belman). The group initially discussed the challenges they were facing in getting these marketing returns measured. (Fig. 7) .
The 'R' in ROI stands for return (i.e. profi t), not revenue, which is a common mistake made in many pharmaceutical company ROI calculations. This mistake could mean that a positive ROI is actually leading to a loss in profi t! To convert this marketing return to ROI, it is often expressed as a percentage of the original investment. The group said that it was under pressure to look at ROI rather than marketing return.
ROI is represented, as shown in Fig. 8 , so that when the gross margin is equal to the marketing investment, the ROI is 0% and the investment is considered to break even. However, most companies set an ROI hurdle rate of 25% or above before funding a project. Theoretically, the hurdle rate should be equal to the discount rate, both of which should represent the company's cost of securing capital. This is often not a practical expectation since the ROI threshold may need to be adjusted higher to account for margins of error in calculations, protecting against potential overlap and recovering general marketing expenses. Sometimes companies base this rate on the level of risk anticipated for the marketing investment.
Where this formula goes wrong was also discussed. The most common errors the group found were as follows:
Using 'revenue' in place of 'return' (i.e. gross margin MINUS the original investment) -in which case you can get a positive ROI but negative profi t.
ROI is applied to marketing as a whole rather than individual discrete marketing investments.
• Only immediate profi t is counted, with future value and net present value not being taken into account in the revenue part of the marketing return calculation.
The total customer life-time value is counted in place of incremental profi ts.
ROI is applied without keeping the 'I' constant. If 'I' is held constant then R -I peaks at the same point as R/ I does. If 'I' is not constant the ratio can be misleading because the immediate reaction to a high ratio is the supposition that more investment would produce the same ratio again -which is clearly fundamentally arithmetically fl awed.
Positive ROI is used as the funding threshold rather than an ROI hurdle rate.
The ROI analysis is not aligned with the marketing decision to be made.
Past ROI has been a poor predictor of future returns for most of the team. ROI relies on historical data (the programme being measured) but relying on history to 'prove' the return on a marketing programme moving forward doesn't guarantee it will pay off in a similar way in the future.
The team discussed how 10 years ago the only thing they were doing was activity tracking (Fig. 9 ). Now they were expected to do ROI and be campaign measurers, but even when they fi gured out the ROI, many assumptions had to be made in their calculations. When they put these same assumptions into their planning, they got signifi cantly different ROI from when they did the same activity the next time.
To combat this, the ideal scenario would use:
Activity tracking to track all performance.
Marketing mix analytics, using current validated market perceptions data, to identify the components of the mix currently driving market performance and 
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to understand the infl uence of competitor activity and environmental factors on current results. This should be tied in mathematically with fi nancial metrics, such as sales or market share and promotional spend, to calculate optimal promotional mix and budget allocation moving forward.
ROI analysis to test results of past programmes, but not as an indicator moving forward.
The roundtable discussion concluded that ROI is a necessary evil but the results should be used only to track past performance rather than being an absolute in terms of future planning; marketing analytics is more suited to that need.
The future of e-detailing: conclusions
Wesley (AstraZeneca) rounded off the conference with an interactive round-up summarizing the key points of the conference. She held a 'Who wants to be a dotcom millionaire?' game show, which highlighted the following points:
We have piloted and proven ROI -now we must implement it.
It's all about CRM.
Impact is vital, so let's embed best practice.
Good e-detailing is good drug education for doctors.
Google is the fi rst stop on the web for most physicians.
Our business models must evolve to put the customer at the centre of everything we do.
The future will not be about 'e' but 'e' will be an integral part of all we do.
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